Optimal antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: A systemic review and meta-analysis

Abstract

A challenge for antithrombotic treatment is patients who present with atrial fibrillation (AF) and acute coronary syndrome, particularly in patients who have undergone coronary percutaneous intervention with stenting (PCIS). In the present study, a total of nine observational trials published prior to July 2017 that investigated the effects of dual antiplatelet therapy (DAPT; aspirin + clopidogrel) and triple oral antithrombotic therapy (TOAT; DAPT + warfarin) among patients with AF concurrent to PCIS were collected from the Medline, Cochrane and Embase databases and conference proceedings of cardiology, gastroenterology and neurology meetings. A meta-analysis was performed using fixed- or random-effect models according to heterogeneity. The subgroups were also analyzed on the occurrence of major adverse cardiac events (MACE), stroke and bleeding events in the two treatment groups. Analysis of baseline characteristics indicated that there was no significant difference in the history of coexistent disease or conventional therapies between the DAPT and TOAT groups. The primary end point incidence was 2,588 patients in the DAPT group (n=13,773) and 871 patients in the TOAT group (n=5,262) following pooling of all nine trials. There was no statistically significant difference in the incidence of primary end points between the DAPT and TOAT groups. Odds ratio (OR)=0.96, 95% confidence interval (CI)=0.73–1.27, P=0.79, with heterogeneity between trials (I2=82%, P<0.00001). Subsequently, on subgroup analysis, the results indicated no increased risk of major bleeding or ischemic stroke in the DAPT or TOAT group. However, compared with the TOAT group, there was an apparent increased risk of MACE plus ischemic stroke in the DAPT group (OR=1.62, 95% CI=1.43–1.83, P<0.00001) with heterogeneity between trials (I2=70%, P=0.01). In conclusion, the present meta-analysis suggests that TOAT (aspirin + clopidogrel + warfarin) therapy for patients with AF concurrent to PCIS significantly reduced the risk of MACE and stroke compared with DAPT (aspirin + clopidogrel) therapy. Further randomized controlled clinical trials are required to confirm the efficacy of the optimal antithrombotic therapy in patients with AF following PCIS.

Antithrombotic Therapy in Atrial Fibrillation and Chronic Ischemic Heart Disease

“…Таким образом, при стентировании коронарных артерий у пациентов с ФП необходимо добавление ПОАК к антиагрегантной терапии, включающей АСК и / или блокатор рецепторов P 2 Y 12 , которое позволяет уменьшить риск развития как тромбоэмболического инсульта, так и тромбоза стента в наиболее опасный период после ЧКВ, однако при этом повышает риск кровотечений [26,27]. Мета-анализ 9 обсервационных сравнительных исследований, включавший данные о 9035 пациентах, убедительно показал преимущества трехкомпонентной антитромботической терапии (ТАТТ) после стентиро-КЛИНИЧЕСКИЕ СЕМИНАРЫ § вания при ФП: у пациентов, дополнительно получавших варфарин, в сравнении с пациентами, принимавшими только АСК в комбинации с клопидогрелом, наблюдалось статистически незначимо больше на 8 % кровотечений, но на 38 % меньше клинически значимых сосудистых осложнений (MACE и ишемический инсульт) [31].…”